Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 1
2009 2
2010 3
2011 2
2012 4
2014 1
2015 2
2016 3
2017 1
2018 3
2019 3
2020 7
2021 5
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Opto-mechanical self-adjustment model of the human eye.
Shahiri M, Jóźwik A, Asejczyk M. Shahiri M, et al. Among authors: jozwik a. Biomed Opt Express. 2023 Apr 5;14(5):1923-1944. doi: 10.1364/BOE.484824. eCollection 2023 May 1. Biomed Opt Express. 2023. PMID: 37206139 Free PMC article.
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S. Dupouy S, et al. Among authors: jozwik a. Cancer Res Commun. 2022 Nov 30;2(11):1520-1531. doi: 10.1158/2767-9764.CRC-22-0175. eCollection 2022 Nov. Cancer Res Commun. 2022. PMID: 36970059 Free PMC article.
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM, Jozwik A, Luong LA, Dominey-Foy D, Graham C, Attwood C, Inam S, Dunlop A, Sanchez K, Cuthill K, Rice C, Streetly M, Bentley T, Boldajipour B, Sommer C, Sasu B, Benjamin R. Metelo AM, et al. Among authors: jozwik a. Cancer Res Commun. 2022 Mar 23;2(3):158-171. doi: 10.1158/2767-9764.CRC-21-0157. eCollection 2022 Mar. Cancer Res Commun. 2022. PMID: 36874402 Free PMC article.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. Benjamin R, et al. Among authors: jozwik a. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. Lancet Haematol. 2022. PMID: 36228643 Clinical Trial.
46 results